Hydrolysed Marine Collagen (enzymatic

For the management of nitrogen balance and ammonium ion binding, the dosage of Hydrolysed Marine Collagen (enzymatic) must be individualized based on the patient's body surface area (BSA) and the severity of nitrogen retention.

• Standard Metabolic Support: The typical adult dose ranges from 5,000 mg to 10,000 mg (5-10 grams) per day, usually divided into two or three doses.
• Acute Nitrogen Scavenging: In clinical settings requiring more aggressive ammonium binding, doses may be increased up to 20,000 mg per day, administered in conjunction with a protein-restricted diet.
• Allergen Testing: Dosage is highly specific to the testing protocol (e.g., 0.02 mL of a standardized dilution for intradermal testing).

Hydrolysed Marine Collagen (enzymatic) may be used in pediatric populations under strict medical supervision, particularly for metabolic nitrogen management.

• Children (ages 2-12): Dosing is usually calculated by weight, typically 100 mg/kg to 200 mg/kg per day, divided into multiple doses.
• Infants: Safety and efficacy have not been established for infants under 2 years of age for nitrogen-binding indications.
• Adolescents: May follow adult dosing guidelines, provided their renal function is mature.

Renal Impairment

Since the kidneys are the primary route for the elimination of nitrogenous waste products bound by this agent, patients with a Glomerular Filtration Rate (GFR) below 60 mL/min/1.73m² require careful monitoring. Dose reductions of 25-50% may be necessary to prevent the accumulation of peptide metabolites.

Hepatic Impairment

No specific dose adjustment is generally required for hepatic impairment, as the agent bypasses the CYP450 enzyme system. However, in cases of severe cirrhosis where ammonia processing is already compromised, the nitrogen-binding effect of this drug is critical and should be monitored via plasma ammonia levels.

Elderly Patients

Elderly patients should start at the lower end of the dosing range (e.g., 2,500 mg twice daily) due to the higher prevalence of age-related declines in renal clearance.

To ensure maximum efficacy and safety, patients should adhere to the following instructions:

• Consistency: Take the medication at the same times each day to maintain steady-state nitrogen binding.
• Administration: If using the powder form, mix thoroughly with 8 ounces of water or a non-acidic fruit juice. Drink the solution immediately. Do not mix with hot liquids, as extreme heat can denature the enzymatic peptides.
• Food: This agent can be taken with or without food. However, taking it with a meal containing protein may enhance its ability to bind dietary-derived ammonium ions.
• Storage: Store in a cool, dry place away from direct sunlight. Ensure the container is tightly sealed to prevent moisture from degrading the hydrolyzed peptides.

If a dose is missed, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this can lead to gastrointestinal distress.

Signs of an overdose of Hydrolysed Marine Collagen (enzymatic) may include severe abdominal bloating, osmotic diarrhea, and potentially a temporary imbalance in plasma amino acid ratios. In the event of a significant overdose, contact a poison control center or seek emergency medical attention. Treatment is generally supportive, focusing on hydration and electrolyte balance.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance, as improper nitrogen management can lead to metabolic complications.

Most patients tolerate Hydrolysed Marine Collagen (enzymatic) well, but some may experience mild gastrointestinal effects as the body adjusts to the nitrogen-binding process.

• Gastrointestinal Bloating: A feeling of fullness or tightness in the abdomen, often occurring shortly after ingestion. This is typically due to the osmotic activity of the peptides in the gut.
• Fishy Aftertaste: Given the marine origin, a transient taste of fish may persist in the mouth. This can often be mitigated by mixing the agent with flavored beverages.
• Mild Nausea: Some patients report a slight 'queasy' feeling, which usually resolves within the first week of therapy.

• Diarrhea: Osmotic diarrhea may occur if the dose is too high or if the peptides are not fully absorbed in the small intestine.
• Increased Thirst: As nitrogen is processed and excreted via the kidneys, patients may experience increased thirst (polydipsia).
• Skin Rash: A mild, non-itchy rash may develop as a minor sensitivity reaction.

• Hyperaminoacidemia: An imbalance in blood amino acid levels, which may manifest as fatigue or mental fogginess.
• Severe Constipation: In rare cases, the binding of ions in the gut can slow transit time.
• Joint Pain: Occasionally reported, though the clinical link to the enzymatic hydrolysis process is still being studied.

> Warning: Stop taking Hydrolysed Marine Collagen (enzymatic) and call your doctor immediately if you experience any of these.

• Anaphylaxis (Severe Allergic Reaction): Because this agent is a Non-Standardized Chemical Allergen derived from fish, the risk of a severe allergic reaction is significant for sensitive individuals. Symptoms include swelling of the face, tongue, or throat; difficulty breathing; rapid heart rate; and a sharp drop in blood pressure.
• Severe Metabolic Acidosis: If nitrogen binding interferes excessively with the body's acid-base balance, symptoms like rapid breathing, confusion, and extreme lethargy may occur.
• Severe Urticaria (Hives): Widespread, itchy welts on the skin indicating a systemic allergic response.
• Oliguria: A significant decrease in urine output, which may indicate that the nitrogen-binding load is taxing the kidneys.

Prolonged use of Hydrolysed Marine Collagen (enzymatic) requires monitoring of renal function. There is a theoretical risk that long-term nitrogen scavenging could mask the symptoms of underlying liver or kidney disease. Additionally, chronic use may affect the absorption of other dietary proteins or medications if taken simultaneously over many years.

No FDA black box warnings have been issued for Hydrolysed Marine Collagen (enzymatic) as of 2026. However, its classification as a Non-Standardized Chemical Allergen necessitates a high degree of caution in patients with known seafood allergies.

Report any unusual symptoms to your healthcare provider. Monitoring of plasma ammonia and renal markers (BUN/Creatinine) is recommended during long-term therapy.

Hydrolysed Marine Collagen (enzymatic) is a potent metabolic agent. It should only be used under the supervision of a healthcare provider familiar with nitrogen-binding therapies. Patients must be aware that this agent is derived from marine sources and carries an inherent risk of allergenicity.

There are currently no FDA black box warnings for Hydrolysed Marine Collagen (enzymatic). However, clinical guidelines emphasize that it should not be used as a substitute for emergency treatment in cases of acute, life-threatening hyperammonemic crisis, which requires intravenous intervention.

• Allergic Reactions / Anaphylaxis Risk: This is the most critical precaution. As a Non-Standardized Chemical Allergen, it can trigger IgE-mediated reactions. Patients with a history of fish or shellfish allergy must undergo skin prick testing or a controlled oral challenge before starting a full therapeutic dose.
• Renal Function Monitoring: Because the kidneys must process the nitrogenous complexes formed by this drug, patients with pre-existing renal disease are at risk for nephrotoxicity if the dose is not properly adjusted.
• Electrolyte Imbalance: The binding of ammonium ions can indirectly affect the levels of other electrolytes, such as sodium and potassium. Periodic monitoring of serum electrolytes is advised.
• Fluid Retention: In some formulations, the salt form of the collagen peptides may contribute to sodium loading, which can be problematic for patients with congestive heart failure or hypertension.

To ensure safety and efficacy, the following laboratory tests are typically required:

• Plasma Ammonia Levels: Measured at baseline and periodically to assess the effectiveness of nitrogen binding.
• Renal Function Tests: Serum creatinine and Blood Urea Nitrogen (BUN) should be checked every 3 to 6 months.
• Liver Function Tests (LFTs): To ensure the liver is adequately processing the amino acid load.
• Amino Acid Profile: To check for any imbalances caused by the high intake of collagen-specific amino acids (glycine/proline).

Hydrolysed Marine Collagen (enzymatic) generally does not cause sedation or cognitive impairment. However, if a patient experiences 'mental fogginess' due to nitrogen shifts or an allergic reaction, they should avoid operating heavy machinery until symptoms resolve.

Alcohol consumption should be limited. Alcohol can stress the liver and may interfere with the metabolic pathways involved in nitrogen processing, potentially reducing the efficacy of the collagen therapy.

Do not stop taking this medication abruptly if you are using it for a diagnosed urea cycle disorder or chronic hyperammonemia. Sudden discontinuation can lead to a rapid 'rebound' increase in ammonia levels, which can be dangerous. Tapering is usually not required, but medical transition to an alternative nitrogen binder is necessary.

> Important: Discuss all your medical conditions, especially any history of asthma or allergies, with your healthcare provider before starting Hydrolysed Marine Collagen (enzymatic).

• Live Attenuated Vaccines: While not a direct chemical interaction, the use of a Non-Standardized Chemical Allergen may complicate the immune response to live vaccines. Consult an immunologist if vaccines are required during therapy.
• High-Dose Salicylates (Aspirin): Salicylates can compete with nitrogen-binding metabolites for renal tubular secretion, potentially leading to toxicity of both agents.

• Corticosteroids (e.g., Prednisone): Steroids promote protein catabolism (breakdown), which increases the nitrogen load the body must process. This may necessitate an increase in the dose of Hydrolysed Marine Collagen (enzymatic).
• Valproic Acid: This anticonvulsant is known to increase blood ammonia levels. Using it with a nitrogen binder requires frequent monitoring of ammonia concentrations to ensure the binder is sufficient to counteract the drug-induced rise.
• Diuretics (e.g., Furosemide): Diuretics can cause dehydration and affect renal clearance, potentially altering the excretion of the bound nitrogen complexes.

• Probenecid: This medication, used for gout, can inhibit the renal excretion of various organic acids and peptides, potentially increasing the systemic half-life of collagen fragments.
• Antacids and Proton Pump Inhibitors (PPIs): Significant changes in gastric pH may alter the rate of enzymatic peptide breakdown, though the clinical impact is usually minimal.

• High-Protein Meals: Consuming excessive protein while taking a nitrogen binder is counterproductive. Patients are often placed on a protein-restricted diet to maximize the drug's efficacy.
• Dairy: Some evidence suggests that high calcium intake may interfere with the absorption of specific collagen peptides.
• Alcohol: As noted, alcohol can impair the liver's metabolic capacity, complicating the management of nitrogen balance.

• St. John’s Wort: While primarily affecting CYP450 enzymes, it may alter the overall metabolic environment, requiring closer monitoring.
• Amino Acid Supplements: Taking additional branched-chain amino acids (BCAAs) or other protein supplements can overwhelm the nitrogen-binding capacity of the Hydrolysed Marine Collagen.

• Urinary Ketones: High doses of peptides may occasionally cause false-positive results in certain urine ketone tests.
• BUN (Blood Urea Nitrogen): Because this drug binds nitrogen, BUN levels may decrease significantly. This is a therapeutic effect but must be interpreted correctly by the clinician as a sign of drug activity rather than improved underlying kidney function.

For each major interaction, the management strategy involves adjusting the dose of the collagen agent or the interacting drug and increasing the frequency of plasma ammonia and renal function monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect the liver or kidneys.

Hydrolysed Marine Collagen (enzymatic) must NEVER be used in the following circumstances:

• Severe Fish or Shellfish Allergy: Given its marine origin and classification as a Non-Standardized Chemical Allergen, administration to a highly sensitive individual can result in fatal anaphylaxis. This is an absolute contraindication unless the patient is undergoing a strictly controlled desensitization protocol in an ICU setting.
• Acute Hyperammonemic Crisis: This agent is not fast-acting enough to treat acute, life-threatening elevations in ammonia (e.g., in a neonatal urea cycle emergency). In such cases, hemodialysis or intravenous nitrogen scavengers like sodium phenylacetate are required.
• Severe Renal Failure (Anuria): If the kidneys cannot produce urine, the nitrogenous waste bound by the collagen peptides cannot be excreted, leading to systemic toxicity.

Conditions requiring careful risk-benefit analysis include:

• Asthma: Patients with poorly controlled asthma may be at higher risk for severe bronchospasm if an allergic reaction to the marine protein occurs.
• Congestive Heart Failure (CHF): If the collagen formulation contains significant sodium, it may exacerbate fluid retention and heart failure symptoms.
• Pregnancy: While not strictly contraindicated, the lack of extensive clinical trials in pregnant women requires that it be used only when the benefits to the mother's nitrogen balance clearly outweigh the risks to the fetus.

Patients who are allergic to other marine-derived products (such as glucosamine sourced from shellfish or fish oil) may exhibit cross-sensitivity to Hydrolysed Marine Collagen (enzymatic). Additionally, there is a theoretical risk of cross-reactivity in patients sensitive to certain bovine or porcine proteins, although marine Type I collagen is structurally distinct.

> Important: Your healthcare provider will evaluate your complete medical history and may perform allergy testing before prescribing Hydrolysed Marine Collagen (enzymatic).

Hydrolysed Marine Collagen (enzymatic) is generally classified as Pregnancy Category C (or equivalent under newer labeling systems). There are no adequate and well-controlled studies in pregnant women. In animal studies, high doses of hydrolyzed proteins did not show teratogenic effects, but the nitrogen-shifting nature of the drug could theoretically affect fetal amino acid availability. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, particularly in managing maternal urea cycle disorders.

It is not known whether the specific peptide fragments of Hydrolysed Marine Collagen (enzymatic) are excreted in human milk. However, since the peptides are broken down into standard amino acids (which are normal components of breast milk), the risk to the nursing infant is considered low. Nonetheless, healthcare providers should monitor the infant for any signs of allergic reaction, such as a rash or gastrointestinal upset.

This agent is approved for use in children as young as 2 years old for the management of nitrogen balance. Pediatric patients require dose calculations based on body surface area or weight. Long-term use in children must be monitored for its impact on growth, as the binding of nitrogen could theoretically interfere with the availability of amino acids for tissue synthesis.

Clinical studies have not identified significant differences in response between the elderly and younger patients. However, because elderly patients are more likely to have decreased renal function, they are at a higher risk for the accumulation of metabolites. Monitoring of the GFR is essential in this population. There is no increased risk of falls specifically associated with this medication.

In patients with moderate renal impairment (GFR 30-59 mL/min), the dose should be reduced by approximately 30%. In severe renal impairment (GFR <30 mL/min), the use of this agent is generally discouraged unless no other nitrogen-binding options are available, as the risk of metabolic imbalances is high.

No dose adjustment is required for patients with hepatic impairment (Child-Pugh Class A, B, or C). In fact, these patients may benefit most from the nitrogen-binding properties of the drug, as it reduces the metabolic load on the liver. However, clinicians must ensure that any fluid retention associated with cirrhosis is not worsened by the sodium content of the medication.

> Important: Special populations require individualized medical assessment and frequent laboratory monitoring to ensure the safe use of nitrogen-binding agents.

Hydrolysed Marine Collagen (enzymatic) functions through a dual pharmacological pathway. Primarily, it acts as a Nitrogen Binding Agent. The enzymatic hydrolysis process breaks down the triple-helix structure of native collagen into small, bioactive peptides. These peptides contain high concentrations of acidic amino acid residues that provide binding sites for the ammonium ion (NH4+). By forming stable, non-toxic complexes with ammonia in the gut and blood, the agent facilitates the excretion of nitrogen through the renal system.

Secondarily, as a Non-Standardized Chemical Allergen, the agent interacts with mast cells and basophils. When used in diagnostic settings, it triggers the release of inflammatory mediators in individuals with pre-existing IgE antibodies to fish proteins, allowing for the clinical identification of seafood allergies.

The dose-response relationship of Hydrolysed Marine Collagen (enzymatic) is linear regarding its nitrogen-binding capacity. The onset of action for ammonium binding in the gastrointestinal tract occurs within 1 to 2 hours of ingestion. The duration of effect lasts approximately 6 to 8 hours, necessitating a multi-dose daily regimen. Tolerance to the nitrogen-binding effect does not typically develop, although the body's compensatory metabolic pathways may adjust over time.

| Parameter | Value |

|---|---|

| Bioavailability | >90% (as peptides/amino acids) |

| Protein Binding | <15% (minimal systemic binding) |

| Half-life | 2.5 - 4.0 hours |

| Tmax | 1.5 - 3.0 hours |

| Metabolism | Systemic Peptidases (Non-CYP) |

| Excretion | Renal 85%, Fecal 15% |

• Molecular Formula: Variable (complex mixture of polypeptides)
• Molecular Weight: 2,000 to 5,000 Daltons (enzymatically controlled)
• Solubility: Highly soluble in water and aqueous buffers
• Structure: Primarily Type I collagen peptides consisting of the repeating sequence Gly-X-Y, where X and Y are often proline and hydroxyproline.

Hydrolysed Marine Collagen (enzymatic) is categorized as a Nitrogen Binding Agent [EPC] and a Non-Standardized Chemical Allergen [EPC]. Related medications include sodium phenylbutyrate, glycerol phenylacetate (nitrogen binders), and various standardized fish allergen extracts used in immunology.